NasdaqGM:RTRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases.


Snowflake Analysis

Mediocre balance sheet with limited growth.


Similar Companies

Share Price & News

How has Retrophin's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RTRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.4%

RTRX

2.5%

US Biotechs

1.7%

US Market


1 Year Return

1.1%

RTRX

26.3%

US Biotechs

6.0%

US Market

Return vs Industry: RTRX underperformed the US Biotechs industry which returned 26.7% over the past year.

Return vs Market: RTRX underperformed the US Market which returned 7.4% over the past year.


Shareholder returns

RTRXIndustryMarket
7 Day2.4%2.5%1.7%
30 Day28.4%7.9%-0.5%
90 Day33.7%25.4%17.8%
1 Year1.1%1.1%27.5%26.3%8.2%6.0%
3 Year10.4%10.4%34.3%29.8%36.3%27.4%
5 Year-41.4%-41.4%-2.9%-8.5%63.0%45.0%

Price Volatility Vs. Market

How volatile is Retrophin's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Retrophin undervalued compared to its fair value and its price relative to the market?

3.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: RTRX ($20.89) is trading above our estimate of fair value ($7.29)

Significantly Below Fair Value: RTRX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: RTRX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: RTRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RTRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RTRX is overvalued based on its PB Ratio (4x) compared to the US Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Retrophin forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

29.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RTRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RTRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RTRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RTRX's revenue (23.5% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: RTRX's revenue (23.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RTRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Retrophin performed over the past 5 years?

-50.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RTRX is currently unprofitable.

Growing Profit Margin: RTRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RTRX is unprofitable, and losses have increased over the past 5 years at a rate of -50.9% per year.

Accelerating Growth: Unable to compare RTRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RTRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: RTRX has a negative Return on Equity (-46.35%), as it is currently unprofitable.


Next Steps

Financial Health

How is Retrophin's financial position?


Financial Position Analysis

Short Term Liabilities: RTRX's short term assets ($406.6M) exceed its short term liabilities ($68.1M).

Long Term Liabilities: RTRX's short term assets ($406.6M) exceed its long term liabilities ($279.2M).


Debt to Equity History and Analysis

Debt Level: RTRX's debt to equity ratio (88.6%) is considered high.

Reducing Debt: RTRX's debt to equity ratio has increased from 50.1% to 88.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RTRX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if RTRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Retrophin current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RTRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RTRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RTRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RTRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RTRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Eric Dube (47yo)

1.5yrs

Tenure

US$9,679,319

Compensation

Dr. Eric M. Dube Ph.D. is Head of North America of ViiV Healthcare Limited. Dr. Dube serves as President and Chief Executive Officer at Retrophin, Inc since January 4, 2019 and its Director since January 2 ...


CEO Compensation Analysis

Compensation vs Market: Eric's total compensation ($USD9.68M) is above average for companies of similar size in the US market ($USD3.13M).

Compensation vs Earnings: Insufficient data to compare Eric's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Eric Dube
President1.5yrsUS$9.68m0.010% $104.5k
Laura Clague
CFO & Senior VP5.67yrsUS$1.30m0.039% $406.8k
William Rote
Senior VP and Head of Research & Development3.5yrsUS$1.31m0.047% $490.7k
Noah Rosenberg
Chief Medical Officer2yrsUS$1.37m0.054% $558.4k
Peter Heerma
Chief Commercial Officer0.75yrUS$1.33mno data
Chris Cline
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Elizabeth Reed
Senior VP3.5yrsUS$1.59m0.051% $531.2k
Casey Logan
Vice President of Corporate Development2.33yrsno datano data

2.3yrs

Average Tenure

51yo

Average Age

Experienced Management: RTRX's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Eric Dube
President1.5yrsUS$9.68m0.010% $104.5k
Stephen Aselage
Director7.75yrsUS$1.26m0.45% $4.7m
John Orwin
Independent Director3.33yrsUS$243.15k0.024% $248.0k
Gary Lyons
Independent Chairman of the Board4.17yrsUS$265.65k0.068% $710.2k
Stuart Swiedler
Member of Scientific Advisory Boardno datano datano data
Roy Baynes
Independent Director4.08yrsUS$243.15k0.028% $292.4k
Timothy Coughlin
Independent Director5.33yrsUS$255.65k0.064% $668.4k
Ron Squarer
Independent Director3.25yrsUS$238.15k0.024% $248.0k
Jeffrey Meckler
Independent Director5.75yrsUS$250.15k0.13% $1.3m
Alan Beggs
Member of Scientific Advisory Boardno datano datano data

4.1yrs

Average Tenure

55yo

Average Age

Experienced Board: RTRX's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RTRX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.8%.


Top Shareholders

Company Information

Retrophin, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Retrophin, Inc.
  • Ticker: RTRX
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.037b
  • Shares outstanding: 49.66m
  • Website: https://www.retrophin.com

Number of Employees


Location

  • Retrophin, Inc.
  • 3721 Valley Centre Drive
  • Suite 200
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RTRXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDDec 2012
17RDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2012

Biography

Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company’s product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health’s National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/07 23:58
End of Day Share Price2020/07/07 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.